Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
5.77
-0.46 (-7.38%)
At close: May 19, 2026, 4:00 PM EDT
5.68
-0.09 (-1.52%)
After-hours: May 19, 2026, 7:28 PM EDT
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $422.00K in the quarter ending March 31, 2026, with 197.18% growth. This brings the company's revenue in the last twelve months to $839.00K, down -96.86% year-over-year. In the year 2025, Silence Therapeutics had annual revenue of $559.00K, down -98.71%.
Revenue (ttm)
$839.00K
Revenue Growth
-96.86%
P/S Ratio
324.84
Revenue / Employee
$9,534
Employees
88
Market Cap
272.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 559.00K | -42.70M | -98.71% |
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.79M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| REGENXBIO | 87.82M |
| Cellectis | 75.11M |
| Compugen | 72.66M |
| Abeona Therapeutics | 14.54M |
| AC Immune | 4.62M |
| Inhibikase Therapeutics | 1.00 |
SLN News
- 1 day ago - Silence Therapeutics files $300M ordinary shares offering - TheFly
- 7 days ago - Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference - Business Wire
- 11 days ago - Silence Therapeutics price target lowered to $27 from $35 at Chardan - TheFly
- 12 days ago - Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year - TheFly
- 12 days ago - Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results - Business Wire
- 2 months ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 5 months ago - Silence Therapeutics CEO Craig Tooman to end employment - TheFly
- 5 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire